Pharma erupts as Biden administration backs waiver of vaccine patent rights
The Biden administration’s call to waive patent rights for coronavirus vaccines sparked vociferous opposition from drugmakers and pharma industry groups, which quickly claimed the move will discourage future drug research and do little to increase supply. Activists, who have pressured the administration for months on the issue, argue a waiver is needed to begin removing… Read More »
